Novel pyrazolo[1,5-a]pyrimidines as c-Src kinase inhibitors that reduce IKr channel blockade

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 2, 2008, Pages 909-921

  Mukaiyama, Harunobu ^a   Nishimura, Toshihiro ^a   Kobayashi, Satoko ^a   Komatsu, Yoshimitsu ^a   Kikuchi, Shinji ^a   Ozawa, Tomonaga ^a   Kamada, Noboru ^a   Ohnota, Hideki ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

c Src; Central nervous system (CNS) penetration; Delayed cardiac current rectifier K+ (IKr) channel; Middle cerebral artery (MCA) occlusion

Indexed keywords

2 (3,5 DIMETHOXYPHENYLAMINO) 7 (1 BENZYL 2 HYDROXYETHYLAMINO) 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (1 HYDROXYMETHYL 2 METHYLPROPYLAMINO) 5 ISOPROPYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (1 HYDROXYMETHYL 2 METHYLPROPYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (1 HYDROXYMETHYL 2 METHYLPROPYLAMINO) 5 PHENYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (2 HYDROXY 1 METHYLETHYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (2 HYDROXYMETHYL 2 METHYLPROPYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (2 HYDROXYPROPYLAMINO) 5 METHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (1 HYDROXYMETHYL 2 METHYLPROPYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (1 HYDROXYMETHYL 2 PYRIDIN 3 YLETHYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO) 7 (2 HYDROXYMETHYLPYRROLIDIN 1 YL)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO) 7 [2 HYDROXY 1 (1H INDOL 3 YMETHYL)ETHYLAMINO]PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 ( 1 BENZYL 2 HYDROXYETHYLAMINO) 5 CYCLOPROPYL 2 (3,5 DIMETHOXYPHENYLAMINO)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; 7 AMINO 5 CYCLOPROPYL 2 PHENYLAMINOPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; AMINOALCOHOL; ETHYLENEDIAMINE DERIVATIVE; LEAD; PHOSPHOTRANSFERASE INHIBITOR; POTASSIUM CHANNEL; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; MIDDLE CEREBRAL ARTERY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; PYRIMIDINES; RATS; SRC-FAMILY KINASES;

RATTUS;

EID: 38549179003     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.10.068     Document Type: Article

References (28)

1. Thomas S.M., and Brugge J.S. Annu. Rev. Cell Dev. Biol. 13 (1997) 513
2. Yu X.-M., Askalan R., Keil II G.J., and Salter M.W. Science 275 (1997) 674
3. Lu W.-Y., Xiong Z.-G., Lei S., Orser B.A., Dudek E., Browning M.D., and MacDonald J.F. Nat. Neurosci. 2 (1999) 331
4. Mócsai A., Ligeti E., Lowell C.A., and Berton G. J. Immunol. 162 (1999) 1120
5. Jope R.S., Zhang L., and Song L. Arch. Biochem. Biophys. 376 (2000) 365
6. Zheng Z.G., Zhang L., Jiang Q., Zhang R., Davies K., Powers C., van Bruggen N., and Chopp M. J. Clin. Invest. 106 (2000) 829
7. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. Mol. Cell 4 (1999) 915
8. Paul R., Zhang Z.G., Eliceiri B.P., Jiang Q., Boccia A.D., Zhang R.L., Chopp M., and Cheresh D.A. Nat. Med. 7 (2001) 222
9. Mukaiyama H., Nishimura T., Shiohara H., Kobayashi S., Komatsu Y., Kikuchi S., Tsuji E., Kamada N., Ohnota H., and Kusama H. Chem. Pharm. Bull. 55 (2007) 881
10. Abbott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy K.W., Keating M.T., and Goldstein S.A. Cell 97 (1999) 175
11. Fermini B., and Fossa A.A. Nat. Rev. Drug Disc. 2 (2003) 439
12. Cavero I., Mestre M., Guillon J.-M., and Crumb W. Exp. Opin. Pharmacother. 1 (2000) 947
13. Cayabyab F.S., and Schlichter L.C. J. Biol. Chem. 277 (2002) 13673
14. Camino D.D., Holmgren M., Liu Y., and Yellen G. Nature 403 (2000) 321
15. Aronov A.M. J. Med. Chem. 49 (2006) 6917
16. Fossa A.A., Depasquale M.J., Raunig D.L., Avery M.J., and Leishman D.J. J. Pharmacol. Exp. Ther. 302 (2002) 828
17. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., and Wrighton S.A. J. Pharmacol. Exp. Ther. 301 (2002) 427
18. Reid W., and Abpul-Fetouh S. Chem-Ztg 113 (1989) 181
19. Katritzky A.R., Pilarski B., and Urogdi L. Synthesis 12 (1989) 949
20. Lu Z., Kamiya K., Opthof T., Yasui K., and Komada I. Circulation 104 (2001) 951
21. Ogata K., and Umeyama H. J. Mol. Graph. Model 18 (2000) 258 305
22. Doyle D.A., Morais Cabral J., Pfuetzner R.A., Kuo A., Gulbis J.M., Cohen S.L., Chait B.T., and MacKinnon R. Science 280 (1998) 69
23. Mitcheson J.S., Chem J., Lin M., Culberson C., and Sanguinetti M.C. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12329
24. Zolotoy A.B., Plouvier B.P., Beatch G.B., Hayes E.S., Wall R.A., and Walker M.J.A. Curr. Med. Chem.: Cardiovasc. Hematol. Agents 1 (2003) 225
25. Umemura K., Wada K., Uematsu T., and Nakashima M. Stroke 24 (1993) 1077
26. Fox T., Coll J.T., Xie X., Ford P.J., Germann U.A., Porter M.D., Pazhanisamy S., Fleming M.A., Galullo V., Su M.S.S., and Wilson K.P. Protein Sci. 7 (1998) 2249
27. Sambrook, J.; Fritsch, E. F.; Maniatis, T. In Molecular Cloning, 2nd ed.; Cold Spring Harbor Laboratory Press, 1989; Vol. 3, pp 16-37.
28. Cheng J., Kamiya K., Liu W., Tsuji Y., Toyama J., and Kodama I. Cardiovasc. Res. 43 (1999) 135